Mesalamine
Proctitis, Proctocolitis, Colitis, Ulcerative + 2 more
Treatment
1 FDA approval
0 Active Studies for Mesalamine
Treatment for
Proctitis
What is Mesalamine
Mesalazine
The Generic name of this drug
Treatment Summary
Mesalazine is a medication used to reduce inflammation in inflammatory bowel disease (IBD). It belongs to the same family of drugs as acetylsalicylic acid (aspirin) and is related to salicylates. Mesalazine has been used to treat and maintain remission for ulcerative colitis, but historically has had difficulty maintaining stability as a pharmaceutical. Recent research initiatives have developed more stable formulations, such as Asacol’s eudragit-S coating and Pentasa’s microgranules. Research into novel methods to stabilize mesalazine continues and its potential to reduce the risk of
Rowasa
is the brand name
Mesalamine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rowasa
Mesalazine
1988
107
Approved as Treatment by the FDA
Mesalazine, otherwise called Rowasa, is approved by the FDA for 1 uses which include Crohn Disease .
Crohn Disease
Effectiveness
How Mesalamine Affects Patients
Mesalazine is one of the two ingredients in the drug sulphasalazine, which is used to treat ulcerative colitis. It works by reducing inflammation and stopping leukocytes from moving and producing free radicals. Mesalazine is mainly effective when taken locally, rather than systemically. In studies with mice and guinea pigs, mesalazine was found to be as effective as prednisone and sulphasalazine in reducing colitis symptoms.
How Mesalamine works in the body
Mesalazine works by blocking the production of pro-inflammatory molecules in the colon. This includes blocking the production of prostaglandins and leukotrienes, which are involved in inflammation. It also activates certain receptors and inhibits enzymes that are linked to inflammation. Additionally, it helps to reduce leukocyte migration and decrease free radical formation, which can reduce inflammation.
When to interrupt dosage
The proposed dose of Mesalamine is contingent upon the specified disorder. The amount of dosage also relies upon the approach of administration outlined in the table below.
Condition
Dosage
Administration
Proctitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Kit, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Tablet, extended release - Oral, Tablet, extended release, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal
Ulcerative Colitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Kit, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Tablet, extended release - Oral, Tablet, extended release, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal
Proctocolitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Kit, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Tablet, extended release - Oral, Tablet, extended release, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal
Crohn Disease
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Kit, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Tablet, extended release - Oral, Tablet, extended release, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal
Colitis, Ulcerative
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Kit, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Tablet, extended release - Oral, Tablet, extended release, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal
Warnings
Mesalamine has eight contraindications, so it should not be administered when one is going through any of the conditions detailed in the ensuing table.
Mesalamine Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Mesalazine may interact with Pulse Frequency
There are 20 known major drug interactions with Mesalamine.
Common Mesalamine Drug Interactions
Drug Name
Risk Level
Description
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Mesalazine.
Methotrexate
Major
The serum concentration of Methotrexate can be increased when it is combined with Mesalazine.
Mifamurtide
Major
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mesalazine.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Neomycin.
Omacetaxine mepesuccinate
Major
The risk or severity of bleeding can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.
Mesalamine Toxicity & Overdose Risk
In two-year studies, mesalazine did not increase the risk of cancer in rats when given up to 320mg/kg/day. It also did not cause any changes to fertility or reproduction. Symptoms of an overdose on mesalazine include nausea, vomiting, fast or deep breathing, ringing in the ears, headache, dizziness, confusion, and seizures. If this happens, treatment can include removing the drug from the body and correcting fluid and electrolyte imbalances. People with kidney problems should be monitored closely when taking mesalazine.
Mesalamine Novel Uses: Which Conditions Have a Clinical Trial Featuring Mesalamine?
Currently, 96 trials are being conducted to assess the potential of Mesalamine to alleviate symptoms of Ulcerative Colitis.
Condition
Clinical Trials
Trial Phases
Proctocolitis
0 Actively Recruiting
Proctitis
0 Actively Recruiting
Crohn Disease
0 Actively Recruiting
Colitis, Ulcerative
0 Actively Recruiting
Ulcerative Colitis
0 Actively Recruiting
Mesalamine Reviews: What are patients saying about Mesalamine?
5
Patient Review
7/2/2022
Mesalamine for Ulcerated Colon
5
Patient Review
2/13/2008
Mesalamine for Ulcerative Colitis currently Without Symptoms
5
Patient Review
8/4/2009
Mesalamine for Crohn's Disease
5
Patient Review
9/6/2011
Mesalamine for Crohn's Disease
4.7
Patient Review
3/14/2012
Mesalamine for Ulcerative Colitis currently Without Symptoms
4.7
Patient Review
1/9/2009
Mesalamine for Ulcerated Colon
4.3
Patient Review
6/2/2009
Mesalamine for Crohn's Disease
4.3
Patient Review
3/22/2019
Mesalamine for Ulcerative Colitis currently Without Symptoms
4.3
Patient Review
3/1/2009
Mesalamine for Crohn's Disease
4
Patient Review
6/8/2020
Mesalamine for Ulcerative Colitis currently Without Symptoms
4
Patient Review
5/6/2017
Mesalamine for Ulcerative Colitis currently Without Symptoms
3
Patient Review
9/24/2011
Mesalamine for Crohn's Disease
3
Patient Review
5/20/2015
Mesalamine for Ulcerative Colitis currently Without Symptoms
2.7
Patient Review
1/1/2016
Mesalamine for Crohn's Disease
2.7
Patient Review
1/13/2008
Mesalamine for Ulcerative Colitis currently Without Symptoms
2.3
Patient Review
5/22/2010
Mesalamine for Ulcerated Colon
2
Patient Review
7/11/2014
Mesalamine for Ulcerative Colitis currently Without Symptoms
1.7
Patient Review
10/17/2017
Mesalamine for Crohn's Disease
Patient Q&A Section about mesalamine
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is mesalamine prescribed for?
"Mesalamine is a medication used to treat and prevent episodes of ulcerative colitis, a condition characterized by inflammation of the bowels. Mesalamine works by reducing inflammation and other symptoms associated with the disease. This medication is only available with a prescription from a doctor."
Answered by AI
When should you take mesalamine?
"Take the Asacol® HD tablet on an empty stomach, at least 1 hour before or 2 hours after a meal. The Lialda® tablets should be taken with food. All other brands of capsules and tablets can be taken with or without food."
Answered by AI
What are the long term effects of taking mesalamine?
"These side effects include worsening colitis; renal toxicity such as interstitial nephritis and nephrotic syndrome; pulmonary toxicity such as interstitial lung disease and fibrosis, bronchiolitis obliterans, pulmonary granulomatosis, and eosinophilic pleural effusion; pericarditis, pancreatitis, hair loss, and Stevens-Johnson syndrome."
Answered by AI
How long can you stay on mesalamine?
"The long-term safety and tolerability of mesalamine granules (MG) therapy was evaluated in the maintenance of UC remission in this study. Studies evaluating different oral mesalamine formulations that came before this one did not exceed a duration of 14 months."
Answered by AI